Discover new options in the treatment of acute myeloid leukemia (AML). Expert faculty explore emerging therapies for initial treatment and for the treatment of patients with relapsed or refractory disease. In-depth discussion of poor-prognosis mutations will provide insight into the best treatment options. Don’t forget to download the tool to help you improve clinician-patient communication.
1.25 AMA PRA Category 1 Credits™
Mar 29, 2019
Mar 29, 2020
Courtney DiNardo, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Mark J. Levis, MD, PhDSidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland, United States
Farhad Ravandi, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Eytan M. Stein, MDMemorial Sloan Kettering Cancer Center
New York, New York, United States
- Newer chemotherapy options
- Treatment for older/unfit patients with AML
- Treatments for FLT3-mutated AML
- IDH1, IDH2 inhibitors
- Clinician-patient communication
This educational activity is specifically designed to meet the needs of practicing hematologists, oncologists/hematologists, oncology nurses, researchers and other healthcare professionals involved and/or interested in the therapeutic management of patients with blood-related cancers and the consequences of these diseases.
After successful completion of this educational activity, participants should be able to:
- Implement best practice treatment protocols for AML that incorporate new and emerging therapies
- Analyze efficacy and safety data from clinical trials evaluating AML treatment options
- Discuss methods to help optimize communications between patients and healthcare providers
This educational activity is supported by grants from Astellas and Jazz Pharmaceuticals.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1.25 hours
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr DiNardo has disclosed that she has received consulting fees from AbbVie, Agios, Celgene Corporation, MedImmune, Jazz, and Syros. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Levis has disclosed that he has received consulting fees from Agios, Amgen, Astellas, Daiichi-Sankyo, Karyopharm, and Novartis Oncology. He has also performed contracted research for Astellas, Fuji Film, and Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Ravandi has disclosed that he has received consulting fees from Agios, Amgen, Astellas, Bristol-Myers Squibb, Celgene Corporation, Macrogenics, and Xencor. He has also performed contracted research for AbbVie, Amgen, Bristol-Myers Squibb, Macrogenics, and Xencor. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Stein has disclosed that he has received consulting fees for membership on advisory boards from Agios; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Novartis Oncology; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director) – worked on non–CME certified projects in the last 12 months supported by Pfizer
- Trudy Stoddert, ELS – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.